World of DTC Marketing

JANUARY 20, 2022

Understanding these trends allows brands to build lasting relationships with customers, improve lead generation, and increase customer lifetime value. We have had the best results when we use long-tail search terms like “what are the side effects of new psoriasis treatments” or “what are the symptoms of depression.”

Digital Media 232

Digital Media Media Pharma Doctors 232

European Pharmaceutical Review

DECEMBER 14, 2023

Between 1999 and 2001, it supported 17 percent of withdrawals, between 2002 and 2011, it supported 26 percent of withdrawals and by 2012 to 2016, 80 percent of withdrawals were supported by observational studies (cohort, case-control, or other epidemiologic design). Meta-analyses contributed least frequently (31.4

Safety 108

Safety Medicine Competition Networking 108

European Pharmaceutical Review

AUGUST 3, 2023

However, the EMA expressed concerns around overall efficacy and, coupled with a concern raised over possible side effects presenting as brain abnormalities suggestive of swelling or bleeding on the brain, led the EMA to the view, following a re-examination process, that it would not recommend the approval of Aduhelm. cited 2023Aug].

Food and Drug Administration 52

Food and Drug Administration Medicine FDA Marketing 52

PM360

JULY 13, 2023

Our lead indications are HER2-positive metastatic breast cancer (mBC) and metastatic castration-resistant prostate cancer (mCRPC). Our clinical data is encouraging and supports potential registrational paths based upon its molecular design focused upon selectivity for cancer-relevant T cells and decreased side effects.

Patients 98

Patients Engineering Side effects Leads 98

European Pharmaceutical Review

SEPTEMBER 22, 2023

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5

Food and Drug Administration 72

Food and Drug Administration Safety Patients Leads 72